The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Director/PDMR Shareholding

22 Mar 2007 12:42

VASTox plc22 March 2007 VASTox plc ("VASTox" or "the Company") Directors' Shareholdings Oxford, UK, 22 March 2007 - VASTox plc (AIM: VOX) has been notified that DrColin Wall, a Non-executive Director of the Company, has today purchased 38,000ordinary shares of 10p each ("Ordinary Shares") at a price of 127 pence pershare. Dr Wall now holds a total of 74,000 shares representing 0.15 per percentof the issued share capital. Colin Wall joined the VASTox Board of Directors in September 2006 as aNon-executive Director and Chairman of the Remuneration Committee. - ends - For more information, please contact: VASTox Steven Lee, PhD, Chief Executive Officer Tel: +44 (0)1235 443951 Darren Millington, Chief Financial Officer Citigate Dewe Rogerson Tel: +44 (0)207 638 9571 Mark Swallow / David Dible / Valerie Auffray About VASTox plc VASTox is a leading UK biotechnology company that discovers and developsproprietary new drugs. The Company's internal drug development programmes areunderpinned by its advanced chemistry and drug screening (chemical genomics)technology platforms, which it also provides on a collaborative orfee-for-service basis to the pharmaceutical industry. VASTox has a broad range of drug discovery programmes in the clinical,pre-clinical and discovery stages of development, which target serious diseaseswith a high unmet medical need. These therapeutic areas include neuro-disorders(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,oncology and regenerative medicines. VASTox's in-house drug development capabilities combine world-class expertise inboth medicinal and carbohydrate chemistry with high-volume, high-contentscreening using its proprietary zebrafish and fruitfly technologies (chemicalgenomics). These whole organism screens have the potential to dramaticallydecrease the time and cost of drug discovery and development by delivering datathat are highly predictive of the efficacy and toxicity of potential drugcompounds in humans. The company listed on the AIM market of the London Stock Exchange in October2004 - symbol: VOX Further information about the company is available at www.vastox.com. This information is provided by RNS The company news service from the London Stock Exchange

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.